Subcutaneous administration of atirizumab can reduce the treatment time for each injection to 4 to 8 minutes (generally 7 minutes), compared to 30-60 minutes for standard intravenous infusion.
The Zhitong Finance App learned that on July 27, the China National Drug Administration Drug Evaluation Center (CDE) official website announced that the marketing application for atrizumab injection (subcutaneous injection) applied by Roche (RHHBY.US) has been accepted. According to public information, attirizumab is a PD-L1 inhibitor that has previously been approved for multiple indications worldwide. The subcutaneous injection form of this product was declared for marketing. Subcutaneous administration of atirizumab can reduce the treatment time for each injection to 4 to 8 minutes (generally 7 minutes), compared to 30-60 minutes for standard intravenous infusion.
Atirizumab (Tecentriq) is a monoclonal antibody that targets PD-L1 developed by Roche. The drug has been approved worldwide for the treatment of various cancers such as non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma, urothelial cancer, PD-L1 positive metastatic triple-negative breast cancer, and advanced melanoma with BRAF V600 mutation. In China, it was approved as a first-line treatment for widespread small cell lung cancer in 2020.